Evidence map›Paper›PMID 35551656›Full record

ArticleCancer treatment and research2022

Melanoma: An immunotherapy journey from bench to bedside.

Vishal Navani, Moira C Graves, Hiren Mandaliya, Martin Hong, Andre van der Westhuizen, Jennifer Martin, Nikola A Bowden

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer treatment and research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vishal NavaniTom Baker Cancer Centre, Calgary, AB, Canada. Vishal.navani@albertahealthservices.ca.
Moira C GravesCentre for Drug Repurposing and Medicines Research, University of Newcastle and Hunter Medical Research Institute, University Dr, Callaghan, NSW, 2308, Australia.
Hiren MandaliyaCalvary Mater Hospital Newcastle, Edith St, Waratah, NSW, 2298, Australia.
Martin HongCalvary Mater Hospital Newcastle, Edith St, Waratah, NSW, 2298, Australia.
Andre van der WesthuizenCentre for Drug Repurposing and Medicines Research, University of Newcastle and Hunter Medical Research Institute, University Dr, Callaghan, NSW, 2308, Australia.
Jennifer MartinCentre for Drug Repurposing and Medicines Research, University of Newcastle and Hunter Medical Research Institute, University Dr, Callaghan, NSW, 2308, Australia.
Nikola A BowdenCentre for Drug Repurposing and Medicines Research, University of Newcastle and Hunter Medical Research Institute, University Dr, Callaghan, NSW, 2308, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma gave science a window into the role immune evasion plays in the development of malignancy. The entire spectrum of immune focused anti-cancer therapies has been subjected to clinical trials in this disease, with limited success until the immune checkpoint blockade era. That revolution launched first in melanoma, heralded a landscape change throughout cancer that continues to reverberate today.

Indexed as

MelanomaProgrammed Cell Death 1 ReceptorB7-H1 AntigenCTLA-4 AntigenHumansImmunotherapyB7-H1 AntigenCTLA-4 AntigenProgrammed Cell Death 1 ReceptorCTLA-4Immune checkpointImmunotherapyImmunotherapy resistanceImmunotherapy responseMelanomaPD-1PD-L1

Identifiers

PMID35551656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.